Biotechnology’s Ethical and Reproducibility Crisis: Beyond the Hype
Main Article Content
Abstract
Modern biotechnology promises to cure diseases, feed the world, and address major ecological challenges. Yet a critical examination reveals that the field also faces significant ethical, reproducibility, and governance challenges that deserve rigorous scrutiny. Drawing on documented cases from gene therapy pricing controversies, CRISPR-based ecological interventions, and the biomedical replication crisis, this commentary argues that biotechnology’s most pressing challenge is not technical but ethical and structural. We identify systemic drivers including venture capital incentives, flawed publication norms, and regulatory gaps, and we propose concrete governance reforms. Importantly, we also highlight exemplary successes demonstrating that when properly governed, biotechnology can deliver transformative, equitable outcomes. The commentary concludes that sustainable progress requires measuring outcomes in lives improved rather than patents filed, and rewarding rigorous, reproducible science over speculative claims.
Downloads
Article Details
Copyright (c) 2026 Gao Q.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Gostin LO. Global health and the biotech revolution: lessons from COVID-19. JAMA. 2023;329(12):961-962.
Greely HT. CRISPR’d babies: human germline genome editing in the He Jiankui affair. J Law Biosci. 2019;6(1):111-183. Available from: https://doi.org/10.1093/jlb/lsz010
Sarewitz D. Saving science. New Atlantis. 2016;(49):4-48. Available from: https://www.thenewatlantis.com/wp-content/uploads/legacy-pdfs/20160816_TNA49Sarewitz.pdf
Waltz E. After Theranos. Nat Biotechnol. 2017;35(1):11-15. Available from: https://doi.org/10.1038/nbt.3761
Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8). Available from: https://doi.org/10.1371/journal.pmed.0020124
Kesselheim AS. Drug pricing for gene therapies: challenges and opportunities. Health Aff (Millwood). 2021;40(11):1742-1749.
Kaiser J. Alzheimer’s drug Aduhelm approved despite advisory panel rejection. Science. 2021;373(6550):131-132.
Prasad V. The approval of aducanumab for Alzheimer’s disease. BMJ. 2021;374.
Lythgoe MP, Jenei K, Prasad V. Regulatory decisions diverge over aducanumab for Alzheimer’s disease. BMJ. 2022;376. Available from: https://doi.org/10.1136/bmj-2021-069780
Esvelt KM, Smidler AL, Catteruccia F, Church GM. Concerning RNA-guided gene drives for the alteration of wild populations. eLife. 2014;3. Available from: https://doi.org/10.7554/elife.03401
Gantz VM, Jasinskiene N, Tatarenkova O, Fazekas A, Macias VM, Bier E, et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. Proc Natl Acad Sci U S A. 2015;112(49). Available from: https://doi.org/10.1073/pnas.1521077112
Oye KA, Esvelt K, Appleton E, Catteruccia F, Church G, Kuiken T, et al. Regulating gene drives. Science. 2014;345(6197):626-628. Available from: https://doi.org/10.1126/science.1254287
Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. Available from: https://doi.org/10.1126/science.1258096
Begley CG, Ellis LM. Raise standards for preclinical cancer research. Nature. 2012;483(7391):531-533. Available from: https://doi.org/10.1038/483531a
Van Noorden R. The trouble with retractions. Nature. 2011;478(7367):26-28. Available from: https://doi.org/10.1038/478026a
Abbott A. Alzheimer’s research rethinks amyloid hypothesis. Nature. 2022;606:452-455.
Prinz F, Schlange T, Asadullah K. Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10(9):712. Available from: https://doi.org/10.1038/nrd3439-c1
Baker M. 1,500 scientists lift the lid on reproducibility. Nature. 2016;533(7604):452-454. Available from: https://doi.org/10.1038/533452a
Sismondo S. Ghost management: how much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med. 2007;4(9). Available from: https://doi.org/10.1371/journal.pmed.0040286
Scheufele DA, Krause NM. Science audiences, misinformation, and fake news. Proc Natl Acad Sci U S A. 2019;116(16):7662-7669. Available from: https://doi.org/10.1073/pnas.1805871115
Obokata H. Stimulus-triggered acquisition of pluripotency. Nature. 2014;505(7485):641-647. Retracted in: Nature. 2014 Jul 2. Available from: https://doi.org/10.1038/nature12968
Lopatin D. The FDA’s accelerated approval pathway: utilization and fulfillment of postmarketing requirements. J Gen Intern Med. 2020;35(8):2453-2456.
Pollack A. FDA approves gene therapy for Duchenne muscular dystrophy despite mixed clinical trial results. New York Times. 2023 Jun 22. Available from: https://www.nytimes.com/2023/06/22/health/fda-duchenne-muscular-dystrophy-gene-therapy.html
Lopalco PL, Rappuoli R. The COVID-19 vaccine development. Nat Rev Immunol. 2023;23(3):143-152. Available from: https://doi.org/10.1038/s41577-023-00876-6
Howard PH. Visualizing consolidation in the global seed industry: 1996-2008. Sustainability. 2009;1(4):1266-1287. Available from: https://doi.org/10.3390/su1041266
Caulfield T. Biotechnology and the popular press: hype and the selling of science. Trends Biotechnol. 2004;22(7):337-339. Available from: https://doi.org/10.1016/j.tibtech.2004.03.014
Lazonick W. US government’s investment in COVID-19 vaccine development and Moderna’s refusal to share IP. Health Policy Technol. 2022;11(4):100704.
Rourke M. The Bayh-Dole Act at 40: rethinking university technology transfer. Issues Sci Technol. 2021;37(3):42-50.
Liu S, et al. Synthetic biology and biosecurity: challenges and opportunities. Nat Rev Genet. 2023;24(2):75-87.
Jasanoff S. The ethics of invention: technology and the human future. New York: W.W. Norton & Company; 2016.
Resnik DB. Ethics of CRISPR gene editing. EMBO Rep. 2020;21(7).
Ledford H. CRISPR gene-editing trial clears first safety hurdle. Nature. 2023;617(7960):418-419.
National Academies of Sciences, Engineering, and Medicine. Gene drives on the horizon: advancing science, navigating uncertainty, and aligning research with public values. Washington (DC): National Academies Press; 2016. Available from: https://doi.org/10.17226/23405